# Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI

> **NCT04232657** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **VA Office of Research and Development** · enrollment: 36 (actual)

## Conditions studied

- Spinal Cord Injury (=3 Years)
- Sublesional Bone Loss Secondary to SCI

## Interventions

- **DRUG:** Romosozumab
- **DRUG:** Denosumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04232657
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-01
- **Primary completion:** 2026-08-01
- **Final completion:** 2027-03-01
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04232657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04232657, "Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04232657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*